Literature DB >> 18569277

Menorrhagia and severe menstrual pain related to the use of adalimumab in a psoriatic.

Noah Scheinfeld1.   

Abstract

The case is reported of a 32-year-old morbidly obese white woman who used adalimumab 40 mg every other week for 4 months for psoriatic arthritis, psoriasis vulgaris and inverse psoriasis with total clearance of her psoriasis who developed menorrhagia (at least twice the number of pads used daily for 4-6 days as opposed to 3-5 days previously) and severe menstrual pain. Treatment with Aviane (ethinyl estradiol and levonorgestrel) abated some of these menstrual symptoms. The symptoms resolved altogether when the adalimumab was discontinued. Menstrual disorders are listed as possible side effects from the use of infliximab and adalimumab in their respective package inserts and also for adalimumab and etanercept in the United Kingdom's Medicines and Healthcare products Regulatory Agency's drug side-effect database, but few case reports of menstrual side effects exist from including tumor necrosis alpha (TNFalpha) blockers. Physicians should be aware of the menstrual side effects of adalimumab and the role of oral contraceptive pills in treating such menstrual side effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18569277     DOI: 10.1080/09546630801955143

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  3 in total

1.  Serious menstrual bleeding associated with use of TNF alpha blocker: two cases.

Authors:  Cemal Bes; Mehmet Soy
Journal:  Rheumatol Int       Date:  2010-03-30       Impact factor: 2.631

Review 2.  Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium.

Authors:  S Haider; M Knöfler
Journal:  Placenta       Date:  2008-11-22       Impact factor: 3.481

3.  The rescue effect of adalimumab in the treatment of refractory pediatric panuveitis complicated with steroid-induced glaucoma.

Authors:  Wei-Ning Ku; Chun-Ju Lin; Yi-Yu Tsai
Journal:  Taiwan J Ophthalmol       Date:  2018 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.